Page last updated: 2024-11-11

n-octyl-beta-valienamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-octyl-beta-valienamine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9817381
CHEMBL ID1234952
CHEMBL ID1922580
SCHEMBL ID21067585
MeSH IDM0299563

Synonyms (10)

Synonym
CHEMBL1234952
n-octylvalienamine
(1s,2s,3r,6r)-4-(hydroxymethyl)-6-(octylamino)cyclohex-4-ene-1,2,3-triol
oev ,
DB08321
CHEMBL1922580 ,
bdbm50358322
n-octyl-beta-valienamine
Q27097540
SCHEMBL21067585
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID731602Induction of beta glucosidase F213I/L444P mutant activity in fibroblasts derived from Gaucher disease patient after 4 days relative to control2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Pharmacological chaperones as therapeutics for lysosomal storage diseases.
AID731601Induction of beta glucosidase N370S mutant activity in fibroblast derived from Gaucher disease patient relative to control2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Pharmacological chaperones as therapeutics for lysosomal storage diseases.
AID731603Induction of beta glucosidase F213I mutant activity in fibroblasts derived from Gaucher disease patient at 30 uM after 4 days relative to control2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Pharmacological chaperones as therapeutics for lysosomal storage diseases.
AID731600Induction of beta glucosidase L444P mutant activity in fibroblast derived from Gaucher disease patient relative to control2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Pharmacological chaperones as therapeutics for lysosomal storage diseases.
AID731641Induction of wild type beta glucosidase activity in fibroblasts derived from Gaucher disease patient after 4 days relative to control2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Pharmacological chaperones as therapeutics for lysosomal storage diseases.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (4.76)18.2507
2000's7 (33.33)29.6817
2010's13 (61.90)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.30

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.30 (24.57)
Research Supply Index3.14 (2.92)
Research Growth Index5.43 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.30)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (13.64%)6.00%
Case Studies1 (4.55%)4.05%
Observational0 (0.00%)0.25%
Other18 (81.82%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]